Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-09-13
2005-09-13
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S235100, C435S455000, C435S456000, C435S457000, C435S472000, C435S473000, C424S093100, C424S093200, C424S093210, C536S023100, C536S023720, C536S024100, C536S024200
Reexamination Certificate
active
06943012
ABSTRACT:
A helper dependent adenoviral vector system is provided. The subject helper dependent adenoviral vector system is made up of: (1) a “gutless” adenoviral vector that include cis-acting human stuffer DNA that provides for in vivo long term, high level expression of a coding sequence present on the vector; (2) an adenoviral helper vector that is characterized by having an adenoviral genome region flanked by recombinase recognition sites, where the helper vectors further include a non-mammalian endonuclease recognition site positioned outside of the adenoviral genome region; and (3) a mammalian cell that expresses the corresponding recombinase and endonuclease, as well as the adenoviral preterminal and polymerase proteins. Also provided are methods of using the subject systems to produce virions having the subject helper dependent adenoviral vectors encapsulated in an adenoviral capsid. In addition, kits for use in practicing the subject methods are provided.
REFERENCES:
patent: 5817492 (1998-10-01), Saito et al.
patent: 5919676 (1999-07-01), Graham et al.
patent: 5985846 (1999-11-01), Kockanek et al.
patent: 6033885 (2000-03-01), Latta et al.
patent: 6066478 (2000-05-01), Lusky et al.
patent: 6080569 (2000-06-01), Graham et al.
patent: 6156497 (2000-12-01), Kaleko
patent: 6228646 (2001-05-01), Hardy
patent: 6468771 (2002-10-01), Einerhand et al.
patent: WO 97/15679 (1997-05-01), None
patent: WO 97/45550 (1997-12-01), None
patent: WO 97/48806 (1997-12-01), None
patent: WO98/13510 (1998-04-01), None
patent: WO 98/17783 (1998-04-01), None
patent: WO99/27101 (1999-06-01), None
patent: WO00/22106 (2000-04-01), None
patent: WO00/49166 (2000-08-01), None
patent: WO 00/49168 (2000-08-01), None
patent: WO 00/49186 (2000-08-01), None
patent: WO00/52187 (2000-09-01), None
patent: WO 01/21824 (2001-03-01), None
Link, CJ. “Adenoviral vectors go retro”, Feb. 2000, Nature Biotechnology vol. 18, p. 150-151.
Zheng, C. “Genomic integration and gene expression by a modified adenoviral vector”, Feb. 2000, Nature Biotechnology vol. 18, p. 176-180.
Recchia, A., “Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector”, PNAS, Mar. 1999. vol. 96 p. 2615-2620.
Kazuhiro et al., “Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor”, Circulation, 2001, vol. 103, no. 9.
Balague et al. “Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector”Blood, Feb. 1, 2000, vol. 95, No. 3 pp. 820-828.
Hartigan-O'Connor “Improved production of gutted Adenovirus in cells expressing Adenovirus preterminal protein and DNA Polymerase”Journal of Virology, Sep. 1999, vol. 73, No. 9 p. 7835-7841.
Lieber et al. “Recombinant Adenovirus with large deletions generated by cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo”,Journal of VirologyDec. 1996, vol. 70, No. 12, p. 8944-8960.
Morral et al. “Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons”PNAS, Oct. 26, 1999, vol. 96. No. 22 pp. 12816-12821.
Parks et al. “Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors”Journal of Virology.
Sandig et al. “Optimization of the helper-dependent adenovirus system for production and potency in vivo”PNAS, Feb. 1, 2000, vol. 97 , No. 3, pp 1002-1007.
Schiedner et al., “Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity”Nature Genetics, vol. 18, Feb. 1998 pp. 180-183.
Zheng et al. “Genomic integration and gene expression by a modified adnoviral vector”Nature Biotechnology, vol. 18, Feb. 2000 pp. 176-180.
Robbins et al. “Viral vectors for gene therapy”Tibtech, Jan. 1998, vol. 16, pp. 35-40.
Kay et al. “Viral vectors for gene therapy: the art of tuming infectious agents into vehicles of therapeutics”Nature Medicine, vol. 7, No. 1.Jan. 2001, pp. 33-40.
Parks et al. “A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 13565-13570, Nov. 1996.
Chen et al. “Persistence in Muscle of an Adenoviral Vector that Lacks all Viral Genes”Proc. Natl. Acad. Sci USA, vol. 94, pp. 1645-1650, Mar. 1997.
Ehrhardt Anja
Kay Mark A.
Baba Edward J.
Bozicevic Field & Francis LLP
Burkhart Michael D.
Field Bret E.
Guzo David
LandOfFree
Helper dependent adenoviral vector system and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Helper dependent adenoviral vector system and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Helper dependent adenoviral vector system and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3384499